VIVEbiotech to participate in BIO International Convention 2026 in San Diego
The company will join the Spain Pavilion by ICEX at one of the leading global events in the biotechnology sector
VIVEbiotech will participate in the BIO International Convention 2026, taking place from June 22 to 25 at the San Diego Convention Center (United States). The event is widely recognized as one of the premier global meeting points for companies, researchers, and investors in the biotechnology industry.
The company’s attendance is part of its ongoing international positioning strategy within the advanced therapies sector. VIVEbiotech specializes in the development and manufacturing of lentiviral vectors for ex vivo and in vivo applications and will use the event to highlight its expertise in supporting the advancement of gene therapies.
From early development to commercial-scale manufacturing, the company provides flexible and tailored solutions adapted to each project’s specific requirements, including titer needs and production scale. Its capabilities encompass a wide range of manufacturing scales, multiple pseudotypes and cell lines, as well as both integrating and non-integrating vectors, supporting diverse vector generations and transgene sizes.
VIVEbiotech’s platform is designed to ensure high quality and performance through advanced purification and processing technologies. The company also brings demonstrated expertise in the development of lentiviral vectors engineered for in vivo applications, along with tailored technology transfer strategies aimed at de-risking innovative pseudotyping approaches and accelerating program development.
This is combined with a strong focus on cost-effectiveness, transparent budgeting, and customized solutions, helping drive the next generation of gene therapies forward.
During the convention, VIVEbiotech will be present at the ICEX – Spain Trade and Investment Pavilion, alongside other organizations from the Spanish biotechnology ecosystem. The pavilion aims to enhance international visibility and foster new collaboration opportunities.
The on-site team will include Jon Alberdi, CEO; Natalia Elizalde, PhD, Chief Business Development Officer; and Peter Jahn, Business Development Vice President, who will take part in meetings and networking activities with key industry stakeholders.
Participation in the BIO International Convention underscores VIVEbiotech’s commitment to advancing innovative gene therapy solutions and strengthening its presence in the global biotech landscape.